Cancer Research Annual Meeting 2010 Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayashi, T.
Right arrow Articles by Faustman, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayashi, T.
Right arrow Articles by Faustman, D. L.
[Cancer Research 62, 24-27, January 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Development of Spontaneous Uterine Tumors in Low Molecular Mass Polypeptide-2 Knockout Mice1

Takuma Hayashi and Denise L. Faustman2

Immunobiology Laboratory, Massachusetts General Hospital-East, and Harvard Medical School, Charlestown, Massachusetts 02129

The presentation of antigenic peptides by MHC class I molecules is important for tumor rejection by CTLs. Such antigenic peptides are generated as a result of the degradation of intracellular proteins by the proteasome pathway, a process that is influenced by the IFN-{gamma}-inducible low molecular mass polypeptide-2 (LMP2) subunit of the proteasome complex. LMP2 knockout mice thus exhibit a defect in proteasome function. Female LMP2-/- mice are now shown to develop uterine neoplasms, with a disease prevalence of ~36% by 12 months of age. This observation indicates that proteasome function is essential for MHC class I-mediated tumor rejection by CTLs.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. E.A. Street, N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth
Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma
Cancer Res., June 1, 2007; 67(11): 5454 - 5460.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. K. Nussbaum, M. P. Rodriguez-Carreno, N. Benning, J. Botten, and J. L. Whitton
Immunoproteasome-Deficient Mice Mount Largely Normal CD8+ T Cell Responses to Lymphocytic Choriomeningitis Virus Infection and DNA Vaccination
J. Immunol., July 15, 2005; 175(2): 1153 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
H.-X. Wang, H.-M. Wang, Q.-L. Li, H.-Y. Lin, D. Qian, and C. Zhu
Expression of Proteasome Subunits Low Molecular Mass Polypeptide (LMP) 2 and LMP7 in the Endometrium and Placenta of Rhesus Monkey (Macaca mulatta) During Early Pregnancy
Biol Reprod, October 1, 2004; 71(4): 1317 - 1324.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.